# Title: **Unveiling the autoreactome: Proteome-wide immunological fingerprints reveal the promise of plasma cell depleting therapy**

## 

- 4 **Authors:** Aaron Bodansky<sup>1</sup>, David JL Yu<sup>2\*</sup>, Alysa Rallistan<sup>3\*</sup>, Muge Kalaycioglu<sup>4\*</sup>, Jim
- 5 Boonyaratanakornkit<sup>5,6</sup>, Damian J. Green<sup>5,6</sup>, Jordan Gauthier<sup>5,6</sup>, Cameron J. Turtle<sup>5,6\*\*</sup>, Kelsey
- 6 Zorn<sup>7</sup>, Brian O'Donovan<sup>7</sup>, Caleigh Mandel-Brehm<sup>7</sup>, James Asaki<sup>8</sup>, Hannah Kortbawi<sup>7,9</sup>, Andrew
- 7 F. Kung<sup>7,10</sup>, Elze Rackaityte<sup>7</sup>, Chung-Yu Wang<sup>12</sup>, Aditi Saxena<sup>12</sup>, Kimberly de Dios<sup>2</sup>, Gianvito
- 8 Masi<sup>13,14</sup>, Richard J. Nowak<sup>13</sup>, Kevin C. O'Connor<sup>13,14</sup>, Hao Li<sup>7</sup>, Valentina E. Diaz<sup>15</sup>, Kaitlin B.
- 9 Casaletto<sup>15</sup>, Eva Q. Gontrum<sup>15</sup>, Brandon Chan<sup>15</sup>, Joel H. Kramer<sup>15</sup>, Michael R. Wilson<sup>16,17</sup>, Paul
- 10 J. Utz<sup>3</sup>†, Joshua A. Hill<sup>5,6</sup>†, Shaun W. Jackson<sup>18,19,20</sup>†, Mark S. Anderson<sup>2</sup>†, Joseph L.
- 11  $DeRisi^{7,12}$ <sup>+</sup>
- 

- \*: These authors contributed equally to this work.
- 14  $\dagger$ : These authors contributed equally to this work.

# **Affiliations:**

- <sup>1</sup> Department of Pediatrics, Division of Critical Care, University of California San Francisco, 18 San Francisco, CA
- 2 Diabetes Center, School of Medicine, University of California San Francisco, San Francisco, CA.
- 3 Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, CA 94305
- 23 <sup>4</sup> Institute of Immunity, Transplantation, and Infection (ITI), Stanford University, Stanford, CA 94305
- <sup>5</sup> Fred Hutchinson Cancer Center, Seattle, WA, USA
- 6 University of Washington School of Medicine, Seattle, WA, USA
- 7 Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA
- 8 29 Biomedical Sciences Program, University of California San Francisco, San Francisco, CA.
- 9 Medical Scientist Training Program, University of California San Francisco, San Francisco, CA.
- <sup>10</sup> Biological and Medical Informatics Program, University of California San Francisco, San Francisco, CA
- 11 Medical Scientist Training Program, University of California San Francisco, San
- Francisco, CA
- Chan Zuckerberg Biohub SF, San Francisco, CA
- 13 Department of Neurology, Yale School of Medicine, New Haven, CT
- 14 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT



It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

#### **Main:**

#### 

#### **Introduction:**

#### 

84 Autoantibodies have been identified in a wide range of autoimmune diseases<sup>1-4</sup>. In many cases 85 these autoantibodies are directly pathogenic  $5-10$ , while in others they amplify or support T cell 86  $\alpha$  driven pathologies<sup>6,11</sup>. Numerous technologies now allow for the detection of autoantibodies to 87 many proteins simultaneously<sup>12–15</sup>, and in the case of phage immunoprecipitation and sequencing 88 (PhIP-Seq), the entire human proteome<sup>16</sup>, using relatively small amounts of plasma or serum. Using these new tools, a wide spectrum of novel autoantibodies have been discovered to be 90 associated with various disease states<sup>11,17–21</sup>, including, but not limited to, paraneoplastic encephalitis, lipodystrophy, inborn genetic disorders, and multisystem inflammatory syndrome in 92 children  $(MIS-C)^{11,16-23}$ . To accurately identify shared autoreactive profiles among individuals that also share a disease state, we and others have found that serum samples from large numbers of healthy individuals are required, due to the presence of highly diverse autoreactivities present 95 in every individual<sup>17</sup>. However, it remains unclear whether individual autoreactive signatures are stable or variable with time or with immunosuppressive treatment. Here, we leveraged a custom proteome-wide PhIP-Seq autoantibody discovery platform to comprehensively profile the autoreactive repertoire in healthy individuals, and discovered that each individual harbors a unique, distinctive, and highly reproducible set of autoreactivities we term the "autoreactome". Using longitudinal samples from an additional cohort of healthy individuals, we determined that

an individuals' autoreactome, once formed, remains minimally changed over the course of years.

 Extending these findings, we explored the impact of B cell depletion therapies upon the autoreactome. Various surface markers are expressed and then downregulated over the course of

105 B cell development and maturation<sup>24,25</sup>. A subset of these surface markers are targeted by B cell

depleting therapies which are used to treat suspected autoantibody mediated diseases, yet a

comprehensive evaluation of the effects of these treatments on autoantibodies remains lacking.

The most commonly used agent, rituximab, targets CD20, which is not expressed by antibody

109 secreting cells<sup>26</sup>. Recently, chimeric antigen receptor T cell (CAR-T) therapy targeting CD19

positive cells was shown to be safe and effective in the treatment of refractory systemic lupus

111 erythematosus  $(SLE)^{27}$ . CD19 is expressed on naive and memory B cells, with reduced

112 expression on plasmablasts and plasma cells<sup>28,29</sup>. CAR-T cells targeting B cell maturation

113 antigen (BCMA), which is expressed primarily by antibody secreting plasma cells<sup>30,31</sup>, are

114 approved for the treatment of multiple myeloma<sup>32,33</sup>. Here, we examined the impact of three

major B cell depleting therapies, rituximab (anti-CD20), anti-CD19 CAR-T cells, and anti-

BCMA CAR-T cells by PhIP-Seq and validate our findings using orthogonal assays. Our

findings demonstrate profound impact of anti-BCMA targeted therapies and minimal impact of

therapies targeting CD19 or CD20 on individuals' autoantibody signatures.

**Healthy individuals harbor a unique set of autoreactivities: the "autoreactome"**

The search for disease causing or associated autoantibodies is confounded by the fact that

autoreactive antibodies are present in all healthy individuals. We have previously shown that

large numbers of healthy samples are required to control for this natural confounder and avoid

124 false positive associations<sup>17</sup>. To better understand the variation of the autoreactive antibodies

between and within healthy individuals, we obtained serum from 79 pre-COVID healthy blood

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

- donors ("Healthy" demographics in Extended Data Table 1) and used our customized, previously
- 127 described 768,000 element phage immunoprecipitation and sequencing platform(PhIP-Seq)<sup>11,17–</sup>
- $^{21,34}$  to determine the proteome-wide set of autoreactivities present within each individual
- (hereafter referred to as the "autoreactome").
- 
- To determine inter- and intra-individual similarity by PhIP-Seq requires high reproducibility as
- measured by technical replicate. Over the past several years, we have refined our PhIP-Seq
- protocols to maximize reproducibility. The master version of this protocol is available at:
- [https://www.protocols.io/view/derisi-lab-phage-immunoprecipitation-sequencing-ph-](https://www.protocols.io/view/derisi-lab-phage-immunoprecipitation-sequencing-ph-czw7x7hn?step=14.1)
- [czw7x7hn?step=14.1.](https://www.protocols.io/view/derisi-lab-phage-immunoprecipitation-sequencing-ph-czw7x7hn?step=14.1) PhIP-Seq protocol performance was evaluated by identifying the PhIP-Seq
- enrichment similarity of 24 sets of technical duplicates using serum from healthy controls. The
- raw signal (reads per 100k; rpk) of each phage-presented peptide which was immunoprecipitated
- within a given sample was calculated, and then used to compare each individual sample.
- Technical replicates showed high reproducibility (Pearson R-coefficient median =0.946; first
- 140 quartile  $(Q1) = 0.907$ , third quartile  $(Q3) = 0.974$ ) (Fig. 1a: Left Panel).
- 

Next, the similarity of individual autoreactomes was compared between each of the 79 healthy

individuals in this study. For each sample, the PhIP-Seq enrichment was compared to each of the

78 other samples. We found that individual autoreactomes were distinctive, with very little

- 145 similarity to others (Pearson R-coefficient median = 0.021; Q1=0.018, Q3=0.023)(Fig. 1a: Right
- Panel).

### 

### **The autoreactome is longitudinally stable**

While individual autoreactomes appear distinct, it remained an open question whether these

- profiles were stable over time within a given individual. To address this question, we performed
- PhIP-Seq on longitudinal serum samples from 7 distinct healthy individuals collected over a
- median of 63 months (35 samples total; Q1=55.5 months, Q3=76 months) ("Longitudinal"
- demographics in Extended Data Table 1). None of these individuals were being treated with
- immunomodulatory agents at any point during sample collection, however one had basal cell
- carcinoma and another had a history of Sjögren's disease (clinical details in Extended Data Table
- 2). We compared the complete PhIP-Seq enrichment profile for each sample to all other samples.
- (Fig. 1b). These results clearly revealed that the intraindividual autoreactome profiles were
- highly correlated (Pearson R-coefficient median=0.883; Q1 =0.817, Q3=0.940). Conversely, the
- autoreactome of longitudinal samples within an individual was significantly more similar to each
- 160 other than to the autoreactomes between different individuals (Mann-Whitney U p-value=4.91e<sup>-1</sup>  $^{95}$ ). Additionally, the distribution of intraindividual correlations overlapped considerably with the
- distribution from technical replicates (104 of 146 (71.2%) longitudinal sample R-values fall
- within 2 standard deviations of the mean of technical replicate R-values), indicating that in most
- cases longitudinal autoreactomes are as similar to one another as technical replicates (Fig. 1c).
- These results suggest that the dominant humoral determinants of autoreactivity within an
- individual are not subject to large variation by this assay, at least within the median 5-year time
- scale of this analysis.
- 

### **Figure 1. Individuals harbor a unique set of longitudinally stable autoreactivities**

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .



# $\frac{170}{171}$

171 **(a)** Correlation matrices showing Pearson correlation coefficients of complete PhIP-Seq signal in

- 172 healthy individuals. Left: 48 samples representing 24 individuals in technical replicate. Right: 79 173 distinct individuals. **(b)** Correlation matrix showing Pearson R-values of complete PhIP-Seq
- 174 signal in 7 distinct individuals each of whom have serial samples over at least 3 years. **(c)** Kernel
- 175 density estimate plot showing distribution of Pearson R correlation coefficients among technical
- 176 replicates, individuals over time, and between different individuals.
- 177

### 178 **The autoreactome is driven by rare autoreactivities and minimally altered by IVIG**

- 179 We and others have used PhIP-Seq to investigate autoimmune disease determinants; however,
- 180 many patients with immune disorders or deficiencies are treated with intravenous
- 181 immunoglobulin (IVIG). IVIG is pooled from thousands of donors<sup>35</sup> and therefore may contain
- 182 relatively common autoantibodies, which has the potential to confound autoantibody assays<sup>36</sup>. To

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

investigate the effect of IVIG on intraindividual PhIP-Seq performance, we examined a cohort of

- 189 samples from patients with myasthenia gravis, an autoantibody-mediated autoimmune
- disease. Among these 189 samples we identified 4 paired sets of samples in which the first
- collection was in a patient naïve to any immunomodulatory treatments, the second sample was
- within 6 weeks of IVIG treatment (2 within days, 1 within 3 weeks, 1 within 6 weeks), and no
- additional immunomodulatory treatments had been given except for steroids and in one case
- azathioprine ("IVIG" demographics in Extended Data Table 1; sample details in Extended Data Table 3).
- 
- 
- PhIP-Seq was performed on these samples, and the mean correlation before and after IVIG was
- 0.815 (relative to 0.87 in longitudinal samples from individuals over time without any
- intervention)(Extended Data Fig. 1a,b). To further determine whether there were directional
- differences in the levels of PhIP-Seq detected autoantibodies following IVIG treatment, the sum
- of the top 10 differentially enriched autoantibodies (see "Methods) derived from each individual
- before and after IVIG administration was compared. No significant difference was observed
- (two-sided paired-samples Wilcoxon test p-value=0.625) (Extended Data Fig. 1c) before and
- after IVIG.
- 

## **Rituximab treatment has minimal effect on the autoreactome**

- Depletion of CD20 positive B cells with rituximab is a common treatment in autoimmunity and
- 203 presumed autoantibody mediated diseases $37-39$ . To determine the extent to which rituximab
- treatment alters the autoreactome, we examined our cohort of 189 samples from patients with
- myasthenia gravis to identify pairs of pre- and post-rituximab treatment samples. Like other
- autoantibody mediated diseases, treatment of myasthenia gravis can include multiple concurrent
- therapies which could potentially alter the autoantibody profile of an individual. To be
- conservative, we excluded all patients who had received any immunomodulation (including
- IVIG and plasma exchange) other than rituximab, steroids, or azathioprine, and for whom a pre-
- treatment sample was not available. Using these stringent criteria, 35 longitudinal samples were
- identified from 7 individuals and analyzed by PhIP-Seq ("Rituximab" demographics in Extended
- Data Table 1; sample clinical details in Extended Data Table 4).
- 
- The PhIP-Seq enrichment profile for each sample from a given individual who received
- rituximab was compared. Despite rituximab therapy, the autoreactome remained overall stable
- within each individual over time (Pearson R-coefficient mean of 0.887; Q1=0.782,
- Q3=0.940)(Fig. 2a). The overall distribution of correlation coefficients from individuals over
- time who received rituximab was similar to individuals who did not receive rituximab (108 of
- 136 (79.4%) within 2 standard deviations of the mean of R-values from longitudinal samples
- without interventions) and was not significantly different (Mann-Whitney U test p-
- 221 value=0.66)(Fig. 2b). While rituximab is known to transiently reduce certain antibodies, these
- results suggest the overall profile of autoreactivity post rituximab treatment remains essentially
- unchanged.
- To determine whether there were decreases in subsets of PhIP-Seq enriched autoreactivities
- following rituximab treatment, as opposed to the complete profile, the sum of the top 10
- differentially enriched protein targets (see "Methods") in each individual were calculated at the
- time of initial sample collection, and then tracked longitudinally following the first dose of

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

- rituximab. To avoid overlapping timelines, datapoints following an additional round of rituximab
- therapy were removed from this analysis. There was no significant difference in the overall
- autoreactivity at 1, 3, or 6 months post-rituximab therapy (one-way paired samples Wilcoxon test
- p-value=0.625 at 1 month, 0.125 at 3 months, and 0.3125 at 6 months) (Fig. 2c). While PhIP-Seq
- enrichment does not report on absolute immunoglobin levels, the levels of the disease-causing
- autoantibody (either anti-AChR or anti-MuSK antibodies) in myasthenia gravis were measured
- independently by a clinical radioimmunoassay (RIA; either Athena Diagnostic or Mayo Clinic
- Laboratory) in 6 of the 7 patients at the same timepoints. Although autoantibody levels minimally decreased in 3 patients, and moderately decreased in the other 3 patients following
- rituximab treatment, they never fell below the established positive cutoff for the assay (Extended
- Data Fig. 2), suggesting that rituximab therapy was unable to quantitatively remove the
- pathogenic autoantibodies.
- 



**Figure 2. Rituximab treatment does not significantly alter the autoreactome**

243<br>244

**(a)** Correlation matrix showing Pearson R-values of complete PhIP-Seq signal in 7 distinct

individuals with myasthenia gravis each of whom were either rituximab naive or had not

- received rituximab for more than 6 months prior to first sample collection. Red arrows represent
- administration of rituximab. **(b)** Kernel density estimate plot showing distribution of Pearson R-
- value correlation coefficients among longitudinal samples from individuals receiving rituximab
- relative to longitudinal samples from individuals received no intervention. **(c)** Lineplots showing
- the autoreactivity (sum of top 10 PhIP-Seq Z-scores relative to the 79 healthy controls) for each
- patient over the first 6 months following initial rituximab dose. One-way paired samples
- Wilcoxon test p-value=0.625 at 1 month, 0.125 at 3 months, and 0.3125 at 6 months.
- 

### **CD19+ B cells are not required to maintain the autoreactome**

- To evaluate the impact of CD19 positive B cell depletion on the autoreactome, PhIP-Seq was
- performed on samples prior to, and approximately 6-months following, anti-CD19 CAR-T
- therapy in 14 individuals being treated for lymphoma ("CD19 CAR-T" demographics in
- 

- of the targeted cells. In 13 of the 14 patients, circulating CD19 cells were either persistently absent (defined as less than 10 CD19+ B cells per microliter) or became absent following 261 treatment. In the remaining patient, only a sample prior to therapy was available, and CD19 B cells were already absent, indicating that they likely remained absent following additional targeted CD19 depleting therapy (Extended Data Fig. 3). None of the individuals had received an allogeneic hematopoietic cell transplant (HCT) in the preceding year (though two had received an autologous HCT), and 12 of the 14 patients were free of any additional B cell depleting therapies for the 6 months prior to initial sample collection. Intravenous immunoglobulin (IVIG) is often administered to patients receiving B cell depleting therapy, and 5 of the 14 patients received IVIG ("CD19" sample clinical details in Extended Data Table 5). The complete PhIP-Seq enrichment profile within each individual before and after CD19 CAR-T therapy was once again compared. Despite depletion or persistently absent CD19 B cells in the 272 setting of active CD19 CAR-T therapy, the autoreactome remained remarkably stable over time 273 (Pearson R-coefficient median =  $0.850$ ;  $Q1 = 0.770$ ,  $Q3 = 0.921$ ) (Fig. 3a). The overall distribution of correlation coefficients in the CD19 CAR-T therapy group was not significantly different from intraindividual variation (Mann Whitney U p-value=0.284) The distribution of correlation values in 12 of the 14 (85.7%) patients fell within the distribution (2 standard deviations from the mean) of longitudinal samples from healthy individuals who received no interventions (Fig. 3b). Using the same analysis approach as described for rituximab, we assessed differential PhIP-Seq enrichments using the sum of top 10 most enriched protein targets before and after CD19 CAR-T treatment (see "Methods"). Of the 14 individuals evaluated, 11 had a decrease in enrichment values while the remaining 3 had an increase, and levels overall were significantly decreased (one-sided paired samples Wilcoxon test p-value=0.021) (Fig. 3c). However, the size of the effect was minimal (median percent decrease in autoreactivity of 11.9%). These results suggest that similar to rituximab, sufficient immunoglobin producing cells remain after treatment such that the pattern of autoreactivity by PhIP-Seq remains largely unaltered. **Figure 3. CD19 CAR-T therapy has minimal effect on the autoreactome 6 months after**
- **treatment**

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .



292 **(a)** Correlation matrix showing Pearson R-values of complete PhIP-Seq signal in 14 distinct individuals before and after anti-CD19 CAR-T therapy. Yellow arrows represent the 6-month post-treatment timepoint. **(b)** Kernel density estimate plot showing distribution of correlation coefficients within each individual before and after therapy relative to the distribution among untreated individuals over time and between different individuals. **(c)** Lineplots showing the autoreactivity (sum of top 10 PhIP-Seq Z-scores relative to the 79 healthy controls) for each patient before and after treatment. One-sided paired samples Wilcoxon test p-value=0.021.

300

301 To orthogonally validate the PhIP-Seq results, serum from 9 of these 14 patients were assayed

302 using a previously described, multiplexed micro-bead assay consisting of 55 known protein

303 autoantigens, each of which was covalently bound to microbeads with distinct barcodes<sup>40</sup>. The

304 list of autoantigens included proteins targeted in connective tissue diseases such as SLE,

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

scleroderma, and myositis, as well as secreted proteins such as cytokines, chemokines and

- growth factors. Additionally, antibody signal to 21 viral antigens was tested to determine
- whether antibodies targeting both self-proteins and viral proteins respond similarly in the
- absence of CD19+ B cells (see Extended Data Table 6 for a list of antigens). Because IVIG
- contains autoantibodies that confound measurements in bead-based assays (our unpublished
- observations), we excluded all patients who had received IVIG within 8 weeks of the initial
- blood draw (pre CAR-T), or had received interim IVIG between the pre CAR-T and post CAR-T
- (6 months after) blood draw. Nine of our 14 patients met these stringent criteria and were included in these experiments.
- 
- As expected, a minority of autoantigens were recognized by serum IgG autoantibodies, including
- 3 intracellular proteins (thyroperoxidase, TPO; bactericidal permeability inducing protein, BPI;
- and pyruvate dehydrogenase complex (PDC)) and 13 secreted proteins. Although levels of
- fourteen of these 16 autoantibodies had decreased signal overall (sum of normalized MFIs; see
- "Methods") following anti-CD19 treatment, this decrease was only statistically significant in one
- case (Extended Data Fig. 4a). Among the 17 antiviral antibodies with meaningful signal, 12 were
- lower following CD19 therapy, but none were statistically significant (Extended Data Fig. 4b).
- These data, generated with an orthogonal platform using full-length proteins as targets confirms
- that the autoreactome, as well as IgG responses to viruses, remain largely stable over time
- following anti-CD19 CAR-T therapy.
- 

## **The autoreactome is profoundly altered following depletion of BCMA positive B cells**

327 While CD19 is known to be expressed on a subset of antibody secreting plasma cells<sup>29</sup>, BCMA is 328 a marker expressed on all plasma cells<sup>31</sup>, making it an attractive target for broad autoantibody

- depletion. To assess the impact of BCMA CAR-T on the autoreactome, we performed PhIP-Seq
- on serum samples from 9 individuals before, and approximately 6-months following, successful
- treatment with BCMA targeted CAR-T therapy ("BCMA" demographics in Extended Data Table
- 1). All 9 individuals had confirmed depletion of plasma cells in bone marrow following anti-
- BCMA CAR-T treatment (Extended Data Fig. 5). Each individual was being treated for multiple
- myeloma, none had received a HCT in the previous year, and 6 of the 9 had not received any
- additional B cell depleting therapy in the prior year. All post-treatment samples were collected at
- least 56 days from the last dose of IVIG, and 3 of the 9 patients never received interim IVIG
- ("BCMA" sample clinical details in Extended Data Table 5).
- 

The complete PhIP-Seq enrichment profile obtained for each individual before and after anti-

- BCMA CAR-T therapy was compared. In contrast to CD19 and CD20 targeting therapies, the
- autoreactome was essentially devoid of any similarity following BCMA targeted therapy
- 342 (Pearson R-value median =  $0.006$ ; Q1= $0.002$ , Q3= $0.130$ ) for 8 of the 9 individuals (Fig. 4a). The
- autoreactome of one individual remained unaltered (R-value = 0.894). This individual was
- subsequently found to have relapsed around the time of sample acquisition, indicating potential
- failure of the CAR-T treatment. The overall distribution of correlation coefficients in the BCMA
- CAR-T therapy group was significantly different from alterations in healthy individuals over
- time without interventions (Mann Whitney U p-value=0.000012)(Fig. 4b). The samples from the
- individual with disease relapse were the only set whose autoreactome remained within 2 standard
- deviations from the mean of individuals over time without treatment. Remarkably, of the
- remaining 8 individuals, 7 of them had autoreactome correlation values following anti-BCMA

- CAR-T therapy that fell within 2 standard deviations of the mean of samples taken from entirely
- different individuals. The observed complete "reset" of the autoreactome in these patients
- suggest that successful treatment with anti-BCMA CAR-T cells sufficiently removes a lifetime
- of accumulated antibody producing plasma cells.
- 
- While the overall autoreactive profile in sera following anti-BCMA CAR-T treatment is
- markedly altered, we also examined changes to the most differentially enriched protein targets
- from pre-treatment samples. Patients with multiple myeloma have a monoclonal expansion of a
- single plasma cell which secretes paraprotein antibody. Because paraprotein is potentially
- autoreactive, and because it is known to dramatically decrease following BCMA CAR-T
- treatment in multiple myeloma, we removed the top two enriched protein targets from each
- individual prior to analysis to minimize the chance that our results were being confounded by
- changes in paraprotein level. The autoreactivity levels for the top 3-12 proteins decreased in every patient follow anti-BCMA CAR-T therapy, and the overall change was statistically
- significant (one-sided paired samples Wilcoxon test p-value=0.0019) (Fig. 4c and 4d). Unlike
- anti-CD19 CAR-T treatment, in which the size of the decrease was minimal, there was a 95.6
- percent decrease in PhIP-Seq enrichment following anti-BCMA CAR-T treatment (Fig. 4e). To
- ensure these findings were similar if the top 10 protein targets were used (and potential
- confounding by paraprotein is not accounted for), the same analysis was performed without the
- removal of the top 2 autoreactivities, with similar findings (Extended Data Fig. 6).
- 
- **Figure 4. Anti-BCMA CAR-T therapy significantly alters the autoreactome**

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .



![](_page_11_Figure_3.jpeg)

374 **(a)** Correlation matrix showing Pearson R-values of complete PhIP-Seq signal in 9 distinct 375 individuals before and after anti-BCMA CAR-T therapy. Yellow arrows represent 6 month post-376 treatment time point. **(b)** Kernel density estimate plot showing distribution of correlation 377 coefficients within each individual before and after BCMA-targeted therapy relative to the 378 distribution among untreated individuals over time, and the distribution between different 379 individuals. **(c)** Heatmap showing top 10 autoreactivities (sum of top 10 PhIP-Seq Z-scores

380 relative to the 79 healthy controls) in each individual before and after treatment. **(d)** Lineplots

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

showing the autoreactivity (sum of top 3 through 12 PhIP-Seq Z-scores relative to the 79 healthy

- controls therefore accounting for potential paraprotein confounding) for each patient before and
- after treatment. One-sided paired samples Wilcoxon test p-value=0.0019. **(e)** Boxplots showing
- the relative distributions of autoreactivity before and after treatment with rituximab (sum of top
- 10), anti-CD19 CAR-T (sum of top 10), and anti-BCMA CAR-T (sum of top 3 through 12
- autoreactivities). Rituximab treatment cohort Mann-Whitney U p-value=0.42 with a median
- percent decrease of 52.3%; anti-CD19 CAR-T treatment cohort Mann-Whitney U p-value=0.206
- with a median percent decrease of 11.9%; rituximab treatment cohort Mann-Whitney U p-value=0.003 with a median percent decrease of 95.6%.
- 
- To orthogonally validate the PhIP-Seq results and further explore the effects of plasma cell
- depletion on antiviral antibodies, we used the same multiplexed bead-based arrays described
- earlier to characterize IgG binding to 55 autoantigens and 21 viral proteins. However, because
- IVIG is routinely given following BCMA CAR-T therapy, only 3 of the original 9 patients were
- IVIG free, so samples from 4 additional patients meeting the stringent criteria outlined
- previously were used (demographics and sample details in Extended Data Tables 7 and 8).
- 
- Of the same 16 measurable autoantigens analyzed in the anti-CD19 CAR-T treatment cohort, 13

had overall decreased IgG binding (sum of normalized MFIs; see "Methods") following anti-

BCMA CAR-T treatment. In contrast to the CD19 CAR-T cohort in which there was only one

- autoantibody with a statistically significant decrease, levels of 9 of the 16 measured
- autoantibodies significantly decreased following anti-BCMA CAR-T therapy (Extended Data
- Figure 7a). Also, unlike the CD19 CAR-T cohort in which levels of none of the anti-viral
- antibodies significantly decreased, all 17 of the measured antiviral antibodies decreased
- following BCMA therapy, and 8 of these decreases were statistically significant (Extended Data
- Figure 7b).

# **Discussion**

- Adaptive immune responses targeting self rather than foreign proteins are a hallmark of
- autoimmune disease. Previous work has noted the existence of circulating self-reactive
- antibodies in healthy individuals. This work has focused on "natural autoantibodies", which are
- thought to arise without antigen stimulation and to consist primarily of unmutated, polyreactive,
- 413 often IgM-class antibodies<sup>41,42</sup>. Despite considerable interest, the role of these antibodies in
- health and disease remains unclear, though there is evidence of variable and context-dependent
- roles; the autoantibodies can contribute to, or protect against, inflammatory and autoimmune
- 416 disease<sup>43–53</sup>. The natural autoantibody repertoire is thought to be relatively shared amongst
- 417 individuals, and to develop during the first few years of life<sup>42,54–56</sup>. Though natural
- autoantibodies may target autoantigens present in autoimmune disease, substantial evidence
- exists that the specific epitope differs from the disease-associated autoantibody, which may in
- 420 part explain why the healthy individuals studied here are clinically immune tolerant  $57,58$ .
- 
- Here, through the targeted application of a custom proteome-wide autoantibody detection
- technology, we find that the repertoire of auto-reactive immunoglobins present in each healthy
- individual is highly distinctive. This "autoreactome" is described by the complex set of
- thousands of peptides reproducibly enriched by immunoprecipitation, and apparently unique to
- each individual. We observe that the autoreactome profile of individuals is remarkably stable,

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

even over years of time, and thus may be considered a "serological fingerprint." In contrast to

- natural autoantibodies, the autoreactome is characterized by uniqueness in each individual, rather
- than a common, shared set of autoreactivities. Interestingly, the stability and uniqueness of the
- autoreactome suggests that our approach may be utilized to de-convolute the origin of an
- unknown patient serum sample in repositories where multiple samples have been collected at
- different timepoints from the same patient.
- 

 During a humoral immune response, plasma cells of varied lifespans are generated, with short- lived plasmablasts providing rapid antibody production in the acute phase and long-lived plasma cells sustaining durable antibody titers. While foreign antigen-specific long-lived plasma cells 437 are known to persist for decades in humans<sup>59–61</sup>, the cellular phenotype of pathogenic plasma cells remains controversial. Since individual autoantibodies decline following therapeutic B cell 439 ablation, despite a lack of CD19 and CD20 expression on plasma cells<sup>27,62,63</sup>, the prevailing model holds that the continuous generation of short-lived plasma cells from memory B cell 441 precursors underlies the autoantibody repertoire<sup>64</sup>. In contrast with this view, we show that not only is the broader intraindividual autoreactome stable over time, but that this autoantibody repertoire is resistant to therapeutic B cell ablation with rituximab (anti-CD20) and anti-CD19 CAR-T cells. Given the expanded options for targeting B cells and plasma cells in systemic autoimmunity, this enhanced understanding of autoreactome biology has important clinical implications. Indeed, by using the autoreactome as a proxy for the autoantibody repertoire within an individual, we show here that depletion of plasma cells via anti-BCMA CAR-T therapy drastically alters the autoantibody repertoires. In most cases, the autoreactome of a sample after

- 449 treatment with BCMA CAR-T cells appears as similar to an entirely different person as to themselves prior to treatment.
- 

 It has been shown that rituximab reduces the level of certain autoantibodies<sup>65</sup>, and has clinical efficacy in many autoimmune disease settings, which may relate more to the antigen presentation

- 454 function of CD20-positive B cells as proposed by others<sup>66</sup>. Additionally, CD19 CAR-T therapy has recently been shown to be effective in the treatment of refractory SLE. Because both anti-
- CD19 CAR-T and anti-BCMA CAR-T are primarily used in the treatment of hematologic
- malignancy, our cohorts received chemotherapy prior to CAR-T therapy, and therefore had low
- CD19 and plasma cells numbers even prior to the initiation of therapy. Future studies will be
- required to further understand the relationship of the pre- and post-CAR-T treatment
- autoreactomes, and its relationship to clinical efficacy, in the specific context of autoimmune
- diseases. Our broad based approach to screen autoantibodies at a proteome wide level allows a
- more comprehensive and unbiased assessment of the effect of therapies on the specificity of the
- autoreactome. We posit that this approach could greatly complement emerging data on the use of
- CAR-T cell therapies that are being utilized against severe autoimmune diseases.
- 
- 466 The prevalence and burden of autoimmune disease continues to rise<sup>67,68</sup>, yet the precise
- mechanisms for the development of autoreactivity remain unclear. There is mounting evidence
- that combinations of genetic and environmental risk factors, including viral infections,
- predispose individuals to disease. In addition to the emerging therapies already discussed, other
- new therapies exist which can halt or prevent the progression of certain autoimmune diseases,
- 471 including type 1 diabetes (T1DM)<sup>69</sup>. By defining the autoreactome and describing the expected
- longitudinal changes over time, we introduce a new tool which can be applied for additional

![](_page_14_Picture_229.jpeg)

- 10. Fröhlich, E. & Wahl, R. Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in
- Thyroid and Extra-Thyroidal Diseases. *Front. Immunol.* **8**, 521 (2017).
- 11. Bodansky, A. *et al.* A distinct cross-reactive autoimmune response in multisystem
- inflammatory syndrome in children (MIS-C). *medRxiv* (2023)
- doi:10.1101/2023.05.26.23290373.
- 12. Wen, X. *et al.* Identification of Novel Serological Autoantibodies in Takayasu Arteritis
- Patients Using HuProt Arrays. *Mol. Cell. Proteomics* **20**, 100036 (2021).
- 13. Wang, E. Y. *et al.* High-throughput identification of autoantibodies that target the human exoproteome. *Cell Rep Methods* **2**, (2022).
- 14. Chang, S. E. *et al.* New-onset IgG autoantibodies in hospitalized patients with COVID-19. *Nat. Commun.* **12**, 5417 (2021).
- 15. Teymennet-Ramírez, K. V., Martínez-Morales, F. & Trejo-Hernández, M. R. Yeast Surface
- Display System: Strategies for Improvement and Biotechnological Applications. *Front*
- *Bioeng Biotechnol* **9**, 794742 (2021).
- 16. Larman, H. B. *et al.* Autoantigen discovery with a synthetic human peptidome. *Nat.*
- *Biotechnol.* **29**, 535–541 (2011).
- 17. Vazquez, S. E. *et al.* Autoantibody discovery across monogenic, acquired, and COVID-19- associated autoimmunity with scalable PhIP-seq. *Elife* **11**, (2022).
- 18. Mandel-Brehm, C. *et al.* Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy. *Diabetes* **72**, 59–70 (2023).
- 19. O'Donovan, B. *et al.* High-resolution epitope mapping of anti-Hu and anti-Yo
- autoimmunity by programmable phage display. *Brain Commun* **2**, fcaa059 (2020).

- 20. Mandel-Brehm, C. *et al.* Kelch-like Protein 11 Antibodies in Seminoma-Associated
- Paraneoplastic Encephalitis. *N. Engl. J. Med.* **381**, 47–54 (2019).
- 21. Vazquez, S. E. *et al.* Identification of novel, clinically correlated autoantigens in the
- monogenic autoimmune syndrome APS1 by proteome-wide PhIP-Seq. *Elife* **9**, (2020).
- 22. Larman, H. B. *et al.* PhIP-Seq characterization of autoantibodies from patients with multiple
- sclerosis, type 1 diabetes and rheumatoid arthritis. *J. Autoimmun.* **43**, 1–9 (2013).
- 23. Xu, G. J. *et al.* Systematic autoantigen analysis identifies a distinct subtype of scleroderma
- with coincident cancer. *Proc. Natl. Acad. Sci. U. S. A.* **113**, E7526–E7534 (2016).
- 24. Sanz, I. *et al.* Challenges and Opportunities for Consistent Classification of Human B Cell
- and Plasma Cell Populations. *Front. Immunol.* **10**, 2458 (2019).
- 25. Khodadadi, L., Cheng, Q., Radbruch, A. & Hiepe, F. The Maintenance of Memory Plasma Cells. *Front. Immunol.* **10**, 721 (2019).
- 26. Pavlasova, G. & Mraz, M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. *Haematologica* **105**, 1494–1506 (2020).
- 27. Mackensen, A. *et al.* Anti-CD19 CAR T cell therapy for refractory systemic lupus
- erythematosus. *Nat. Med.* **28**, 2124–2132 (2022).
- 541 28. Haas, K. M. & Tedder, T. F. Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity. *Adv. Exp. Med. Biol.* **560**, 125–139 (2005).
- 29. Wang, K., Wei, G. & Liu, D. CD19: a biomarker for B cell development, lymphoma
- diagnosis and therapy. *Exp. Hematol. Oncol.* **1**, 36 (2012).
- 30. Tai, Y.-T. & Anderson, K. C. Targeting B-cell maturation antigen in multiple myeloma.
- *Immunotherapy* **7**, 1187–1199 (2015).

- 31. O'Connor, B. P. *et al.* BCMA is essential for the survival of long-lived bone marrow
- plasma cells. *J. Exp. Med.* **199**, 91–98 (2004).
- 32. Cohen, A. D. *et al.* B cell maturation antigen-specific CAR T cells are clinically active in
- multiple myeloma. *J. Clin. Invest.* **129**, 2210–2221 (2019).
- 33. Brudno, J. N. *et al.* T Cells Genetically Modified to Express an Anti-B-Cell Maturation
- Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed
- Multiple Myeloma. *J. Clin. Oncol.* **36**, 2267–2280 (2018).
- 34. Bodansky, A. *et al.* Autoantigen profiling reveals a shared post-COVID signature in fully
- recovered and long COVID patients. *JCI Insight* **8**, (2023).
- 35. Barahona Afonso, A. F. & João, C. M. P. The Production Processes and Biological Effects of Intravenous Immunoglobulin. *Biomolecules* **6**, 15 (2016).
- 36. Burbelo, P. D. *et al.* Autoantibodies detected in MIS-C patients due to administration of
- intravenous immunoglobulin. *bioRxiv* (2021) doi:10.1101/2021.11.03.21265769.
- 37. Narayanaswami, P. *et al.* International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. *Neurology* **96**, 114–122 (2021).
- 
- 38. Hauser, S. L. *et al.* B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. *N. Engl. J. Med.* **358**, 676–688 (2008).
- 39. Marinho, A. *et al.* Biological therapy in systemic lupus erythematosus, antiphospholipid
- syndrome, and Sjögren's syndrome: evidence- and practice-based guidance. *Front.*
- *Immunol.* **14**, 1117699 (2023).
- 40. Ayoglu, B. *et al.* Characterising the autoantibody repertoire in systemic sclerosis following
- myeloablative haematopoietic stem cell transplantation. *Ann. Rheum. Dis.* **82**, 670–680
- (2023).

- 41. Mannoor, K., Xu, Y. & Chen, C. Natural autoantibodies and associated B cells in immunity and autoimmunity. *Autoimmunity* **46**, 138–147 (2013).
- 42. Lacroix-Desmazes, S. *et al.* Self-reactive antibodies (natural autoantibodies) in healthy
- individuals. *J. Immunol. Methods* **216**, 117–137 (1998).
- 43. Mannoor, K., Matejuk, A., Xu, Y., Beardall, M. & Chen, C. Expression of natural
- autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival. *J.*
- *Immunol.* **188**, 3628–3638 (2012).
- 44. Cohen, I. R. & Cooke, A. Natural autoantibodies might prevent autoimmune disease.
- *Immunol. Today* **7**, 363–364 (1986).
- 45. Coutinho, A., Kazatchkine, M. D. & Avrameas, S. Natural autoantibodies. *Curr. Opin. Immunol.* **7**, 812–818 (1995).
- 46. Holodick, N. E., Zeumer, L., Rothstein, T. L. & Morel, L. Expansion of B-1a Cells with
- Germline Heavy Chain Sequence in Lupus Mice. *Front. Immunol.* **7**, 108 (2016).
- 47. Ehrenstein, M. R. & Notley, C. A. The importance of natural IgM: scavenger, protector and regulator. *Nat. Rev. Immunol.* **10**, 778–786 (2010).
- 48. Grönwall, C., Vas, J. & Silverman, G. J. Protective Roles of Natural IgM Antibodies. *Front. Immunol.* **3**, 66 (2012).
- 49. Vas, J., Grönwall, C. & Silverman, G. J. Fundamental roles of the innate-like repertoire of natural antibodies in immune homeostasis. *Front. Immunol.* **4**, 4 (2013).
- 50. Grönwall, C. & Silverman, G. J. Natural IgM: beneficial autoantibodies for the control of
- inflammatory and autoimmune disease. *J. Clin. Immunol.* **34 Suppl 1**, S12-21 (2014).
- 51. Lobo, P. I. Role of Natural Autoantibodies and Natural IgM Anti-Leucocyte Autoantibodies
- in Health and Disease. *Front. Immunol.* **7**, 198 (2016).

- 52. Szinger, D. *et al.* Following Natural Autoantibodies: Further Immunoserological Evidence
- Regarding Their Silent Plasticity and Engagement in Immune Activation. *Int. J. Mol. Sci.*
- **24**, (2023).
- 53. Gál, S. *et al.* Natural and Pathological Autoantibodies Show Age-Related Changes in a
- Spontaneous Autoimmune Mouse (NZB) Model. *Int. J. Mol. Sci.* **24**, (2023).
- 54. Mouthon, L. *et al.* Analysis of the normal human IgG antibody repertoire. Evidence that
- IgG autoantibodies of healthy adults recognize a limited and conserved set of protein
- antigens in homologous tissues. *J. Immunol.* **154**, 5769–5778 (1995).
- 55. Mouthon, L. *et al.* Invariance and restriction toward a limited set of self-antigens
- characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of healthy adults. *Proc. Natl. Acad. Sci. U. S. A.* **92**, 3839–3843 (1995).
- 56. Mouthon, L. *et al.* The self-reactive antibody repertoire of normal human serum IgM is
- acquired in early childhood and remains conserved throughout life. *Scand. J. Immunol.* **44**, 243–251 (1996).
- 57. Piechaczyk, M. *et al.* Antigenic domains on the human thyroglobulin molecule recognized
- by autoantibodies in patients' sera and by natural autoantibodies isolated from the sera of healthy subjects. *Clin. Immunol. Immunopathol.* **45**, 114–121 (1987).
- 58. Ronda, N. *et al.* Analysis of natural and disease-associated autoantibody repertoires: anti-
- endothelial cell IgG autoantibody activity in the serum of healthy individuals and patients
- with systemic lupus erythematosus. *Int. Immunol.* **6**, 1651–1660 (1994).
- 59. Halliley, J. L. *et al.* Long-Lived Plasma Cells Are Contained within the CD19(-
- )CD38(hi)CD138(+) Subset in Human Bone Marrow. *Immunity* **43**, 132–145 (2015).

- 60. Bhoj, V. G. *et al.* Persistence of long-lived plasma cells and humoral immunity in
- individuals responding to CD19-directed CAR T-cell therapy. *Blood* **128**, 360–370 (2016).
- 61. Hill, J. A. *et al.* Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-
- cell therapy. *Am. J. Transplant* **23**, 416–422 (2023).
- 62. Joly, P. *et al.* First-line rituximab combined with short-term prednisone versus prednisone
- alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group,
- open-label randomised trial. *Lancet* **389**, 2031–2040 (2017).
- 63. Fervenza, F. C. *et al.* Rituximab or Cyclosporine in the Treatment of Membranous
- Nephropathy. *N. Engl. J. Med.* **381**, 36–46 (2019).
- 64. Hale, M., Rawlings, D. J. & Jackson, S. W. The long and the short of it: insights into the
- cellular source of autoantibodies as revealed by B cell depletion therapy. *Curr. Opin.*
- *Immunol.* **55**, 81–88 (2018).
- 65. Díaz-Manera, J. *et al.* Long-lasting treatment effect of rituximab in MuSK myasthenia. *Neurology* **78**, 189–193 (2012).
- 66. Hofmann, K., Clauder, A.-K. & Manz, R. A. Targeting B Cells and Plasma Cells in
- Autoimmune Diseases. *Front. Immunol.* **9**, 835 (2018).
- 67. Dinse, G. E. *et al.* Increasing Prevalence of Antinuclear Antibodies in the United States. *Arthritis Rheumatol* **74**, 2032–2041 (2022).
- 68. Miller, F. W. The increasing prevalence of autoimmunity and autoimmune diseases: an
- urgent call to action for improved understanding, diagnosis, treatment, and prevention.
- *Curr. Opin. Immunol.* **80**, 102266 (2023).
- 69. Waibel, M. *et al.* Baricitinib and β-Cell Function in Patients with New-Onset Type 1
- Diabetes. *N. Engl. J. Med.* **389**, 2140–2150 (2023).

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

### **Methods**

#### **Patients**

The "Healthy Control" cohort consists of plasma from 79 self-reported healthy, pre-COVID-19

- individuals which were obtained as deidentified samples from the New York Blood Center.
- These samples were part of retention tubes collected at the time of blood donations from
- volunteer donors who provided informed consent for their samples to be used for research.
- 
- For the bead-based protein arrays, serum and/or plasma was used for internal controls and
- 646 validations, as has been previously described, as deidentified samples<sup>70</sup>. Negative controls
- included a pediatric sample from an infant between 6 and 12 months of age which was a gift
- from the Pulendran lab, as well as samples from 3 healthy subjects with known CMV-
- seronegative status confirmed by ELISA from the Stanford Blood Center. Positive controls
- include plasma samples derived from participants with autoimmune or other types of diseases
- with known reactivity patterns (e.g. thyroid peroxidase [TPO], pyruvate dehydrogenase complex
- [PDC-E2], fibroblast growth factor 7 [FGF7], proteinase 3, IL-11, CXCL-13) which were
- purchased from ImmunoVision or were obtained from Stanford Autoimmune Diseases Biobank and Oklahoma Medical Research Foundation (Oklahoma City, Oklahoma, USA; a gift of Judith
- James, Oklahoma Medical Research Foundation). A total of 12 positive control patient samples
- were used. All 16 of these patients (4 negative controls and 12 positive controls) provided
- informed consent for their samples to be used for research.
- 
- Longitudinal plasma samples were obtained from a set of 7 community dwelling, cognitively
- unimpaired, pre-COVID-19, healthy older adults recruited through the Brain Aging Network for
- Cognitive Health (BrANCH) at the University of California, San Francisco. All participants are
- screened at baseline and enrollment criteria excluded individuals with severe psychiatric illness,
- neurologic disorders (e.g., epilepsy, multiple sclerosis), and medical conditions that could impact
- cognition (e.g., recent substance use disorders, active chemotherapy). Following a
- comprehensive neurobehavioral evaluation, participants were classified cognitively normal per
- consensus conference with board-certified neurologists and neuropsychologists. Inclusion in the
- current study was contingent on no known autoimmune conditions at baseline or follow up visits, either active or inactive at the time of plasma collection. Study procedures were approved by the
- UCSF Committee on Human Research and all participants provided written informed consent
- (IRB #10-02076).
- 
- For the myasthenia gravis patient cohort (used to evaluate the effects of IVIG and rituximab),
- deidentified serum samples from myasthenia gravis patients, with laboratory confirmed AChR or
- MuSK autoantibody serostatus, were retrieved from a biorepository established at the Yale
- School of Medicine, Myasthenia Gravis Clinic (EXPLORE-MG Registry, NCT03792659) under
- the approval of Yale University's Institutional Review Board.
- 
- 678 The CAR-T cell cohorts consisted of adults aged  $\geq$ 18 years with relapsed or refractory CD19+ or
- BCMA+ hematologic malignancies who received lymphodepleting chemotherapy with
- cyclophosphamide and fludarabine followed by anti-CD19 or anti-BCMA-CAR-T cells at Fred
- Hutchinson Cancer Center (Fred Hutch). Serum and PBMCs were prospectively collected once

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

- prior to lymphodepleting chemotherapy and at approximately 6-12 months after CAR-T cell
- infusion among individuals who achieved durable remissions and received no subsequent anti-
- tumor therapies. This work was approved by the Fred Hutch institutional review board (Protocol
- 10080), and all participants provided informed consent in accordance with the Declaration of Helsinki.
- 

## **PhIP-Seq**

- All PhIP-Seq was performed similar to our previously published multichannel protocol, with minor adjustments as outlined in our new protocol: [https://www.protocols.io/view/derisi-lab-](https://www.protocols.io/view/derisi-lab-phage-immunoprecipitation-sequencing-ph-czw7x7hn?step=14.1)
- [phage-immunoprecipitation-sequencing-ph-czw7x7hn?step=14.1](https://www.protocols.io/view/derisi-lab-phage-immunoprecipitation-sequencing-ph-czw7x7hn?step=14.1)
- 
- 693 As previously described<sup>11</sup>, our human peptidome library consists of a custom-designed phage
- library of 731,724 unique T7 bacteriophage each presenting a different 49 amino-acid peptide on
- its surface. Collectively these peptides tile the entire human proteome including all known
- isoforms (as of 2016) with 25 amino-acid overlaps. 1 milliliter of phage library was incubated
- with 1 microliter of human serum overnight at 4C and immunoprecipitated with 25 microliters of
- 1:1 mixed protein A and protein G magnetic beads (Thermo Fisher, Waltham, MA, #10008D and
- #10009D). These beads were than washed, and the remaining phage-antibody complexes were
- eluted in 1 milliliter of E.Coli (BLT5403, EMD Millipore, Burlington, MA) at 0.5-0.7 OD and
- amplified by growing in 37C incubator. This new phage library was then re-incubated with the
- same individual's serum and the previously described protocol repeated. DNA was then
- extracted from the final phage-library, barcoded, and PCR-amplified and Illumina adaptors
- added. Next-Generation Sequencing was then performed using an Illumina sequencer (Illumina,
- San Diego, CA) to a read depth of approximately 1 million per sample.
- 

# **Bead-based protein array**

- A 76-plex protein array comprising a 55-plex autoantigen protein subarray and a 21-plex viral protein subarray was constructed as previously described, with modifications<sup>40</sup>. In brief, antigens (Extended Data Table 6) were conjugated to uniquely barcoded carboxylated magnetic beads (MagPlex-C, Luminex Corp). The beads were stored in aliquots at -80°C after conjugation and thawed on the day of the experiment. 45 µl of diluted serum or plasma sample (1:100 in PBS- 1%BSA) was transferred into the 384-well plate (Greiner BioOne) containing 5 µl of bead array per well. Samples were incubated for 60 min on a shaker at room temperature, and then at 4C 715 overnight. The following day beads were washed with  $4 \times 60$  µl PBS-Tween on a plate washer
- (EL406, Biotek) and then incubated with 50 µl of 1:1000 diluted R-phycoerythrin (R-PE) conjugated Fc-γ-specific goat anti-human IgG F(ab')2 fragment (Jackson ImmunoResearch 109-
- 718 116-170) for 30 min. The plate was washed with  $4 \times 60$  µl PBS-Tween and re-suspended in 50
- µl PBS-Tween prior to analysis using a FlexMap3D TM instrument (Luminex Corp.) and
- measuring MFI with at least 50 beads per barcode for each sample. Most of the individual
- antigens that had been conjugated to beads were qualified prior to mixing using antibodies-
- directed against epitope tags, monoclonal antibodies specific for the antigen, or prototype human
- plasma samples derived from participants with autoimmune diseases with known reactivity
- patterns (e.g., Scl-70+ systemic sclerosis; SSA+, which is associated with lupus and Sjögren's
- syndrome; ribonucleoprotein (RNP)+ sera, which is associated with lupus and mixed connective
- tissue disease; and APS1 sera which are reactive with multiple cytokines; data not shown).

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

- Binding events were displayed as Median Fluorescence Intensity (MFI). MFI values were
- normalized by subtracting bare-bead MFI values. Replicate MFI values were averaged.
- 

### **Enumeration of B cells and plasma cells**

- B cells were quantified using a research flow cytometry panel (Representative gates shown in
- Extended Data Fig. 8). Briefly, peripheral blood mononuclear cells (PBMCs) were incubated on
- ice for 30 minutes with fluorescently labeled antibodies (in fluorescence-activated single cell
- sorting [FACS] buffer containing Dulbecco's phosphate-buffered saline [DPBS] and
- 1% [newborn](https://www.sciencedirect.com/topics/medicine-and-dentistry/neonatal-infant) calf serum [Life Technologies]) before its analysis on a FACSymphony A5 (BD
- Bioscience) flow cytometer. The following antibodies were included for cell labeling: fixable
- viability stain 700 (BD cat#564997), anti-CD19 BV421 (HIB19, BD), anti-CD45 BV510 (HI30,
- BD), anti-CD3 BV605 (UCHT1, BioLegend), anti-CD16 BV711 (3G8, BD), anti-CD14 BV711
- (M0P-9, BD). FlowJoTM Software version 10.7.1 was used for analyses with flow cytometry
- 740 proportions multiplied by absolute lymphocyte counts to calculate total  $CD19<sup>+</sup>$  B cell numbers.
- $P141$  Plasma cells in the bone marrow were quantified based on detection of CD138<sup>+</sup> plasma cells in
- clinically obtained bone marrow core biopsies by [immunohistochemistry](https://www.sciencedirect.com/topics/medicine-and-dentistry/immunohistochemistry) in the University of
- Washington Hematopathology Laboratory.
- 

### **Analysis of PhIP-Seq**

- As previously described<sup>11</sup>, next generation sequencing reads from fastq files were aligned at the
- level of amino acids using RAPSearch2. All results represent the average of technical replicates,
- except for the 79 individual healthy controls in whom only 24 of the individuals (48 samples)
- were performed in technical replicate. All human peptidome analysis was performed at the gene-
- level, in which all reads for all peptides mapping to the same gene were summed, and 0.5 reads
- were added to each gene to allow inclusion of genes with zero reads in mathematical analyses.
- Within each individual sample, reads were normalized by converting to the percentage of total reads. To normalize each sample against background non-specific binding, a fold-change (FC)
- over mock-IP was calculated by dividing the sample read percentage for each gene by the mean
- read-percentage of the same gene for the AG bead only controls. This FC signal was then used
- for side-by-side comparison between samples and cohorts. FC values were also used to calculate
- 
- z-scores for specific cohorts relative to defined controls.
- 

# **Analysis of multiplexed bead arrays**

- Antibody reactivity to each target for each sample was measured in mean fluorescent intensity
- (MFI). Data is only shown for targets which have an MFI of at least 1000 MFI units at any time
- point for any patient. To adjust for background binding to beads only, each sample was
- additionally run on unconjugated beads, and bare bead MFI was subtracted to create an adjusted
- MFI for each target antigen within the same corresponding sample. To account for nonspecific
- binding from human serum, a sample from an infant control known to lack antibodies to any of
- the viral or human targets was run in duplicate. The mean of the adjusted MFI's for the control
- duplicates was calculated for each target, and further subtracted from each corresponding target
- from each sample. A normalization function was then performed such that all sample values for
- each target antigen ranged from zero to one, referred to as "Normalized MFI".
- 
- **Statistical methods**

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

- All statistical analysis was performed in Python using the Scipy Stats package. To calculate the
- overall similarity of PhIP-Seq detected autoreactive profiles between different samples, a
- Pearson correlation coefficient was calculated using all FC over mock-IP values (unless
- specifically stated otherwise) for each autoantigen in each sample relative to each autoantigen in
- each other sample. For comparisons of distributions of PhIP-Seq signal (either autoreactivity
- scores or Pearson R-values) between two groups, a non-parametric Mann-Whitney U test was utilized. To determine whether specific interventions (IVIG, rituximab, anti-CD19 CAR-T, or
- anti-BCMA CAR-T) directionally decreased PhIP-Seq detected autoreactivities, first an
- "autoreactivity" score was calculated by summing the top 10 autoantigen z-scores (relative to the
- 79 healthy controls) in each pre-treatment sample. The sum of the z-scores from these same 10
- autoantigens were again calculated following the intervention for each post-treatment sample
- from the same individual. These autoreactivity scores from before and after a treatment were
- paired within each individual, and used as input for a one-sided paired-samples Wilcoxon test.
- To determine whether anti-CD19 CAR-T treatment, or anti-BCMA CAR-T treatment altered
- Luminex detected antibody levels from the bead-based protein arrays, the pre-treatment and
- post-treatment normalized MFI values were compared using a two-sided paired-samples
- 788 Wilcoxon test for each target antigen. P-values:  $ns > 0.05$ ,  $* < 0.05$ ,  $** < 0.01$ ,  $** < 0.005$ ,  $****$  $789 \leq 0.001$ .
- 

## **Data Availability**

- All PhIP-Seq data will be made publicly available upon publication of this manuscript via a
- Dryad digital repository; DOI: 10.5061/dryad.w3r2280z6
- 

# **Methods References**

70. P. Cheung, F. Vallania, H. C. Warsinske, M. Donato, S. Schaffert, S. E. Chang, M. Dvorak,

- C. L. Dekker, M. M. Davis, P. J. Utz, P. Khatri, A. J. Kuo, Single-Cell Chromatin Modification
- Profiling Reveals Increased Epigenetic Variations with Aging. *Cell*. **173**, 1385-1397.e14 (2018).
- 

# **Acknowledgements**

The authors acknowledge the New York Blood Center for contributing pre-COVID-19 healthy

- donor blood samples. We acknowledge Brian O'Donovan for coining the term "autoreactome".
- The authors would like to thank Quinton R. Markett for assistance with organizing protein array reagents and design.
- 

# **Author Contributions**

- Conceptualization: A.B., H.L., M.R.W., J.A.H., S.W.J., M.S.A., J.L.D. Methodology: A.B., J.A.,
- A.F.K., H.K., E.R., C.Y.W., A.S., P.J.U., A.R., M.K., M.S.A., J.L.D. Performed or contributed
- to experiments: A.B., D.J.L.Y., A.R., M.K., J.B., C.M.B., B.O. Formal analysis: A.B., J.L.D.
- 810 Patient sample and clinical data acquisition: K.Z., K.D.D., V.E.D., E.Q.G., B.C., D.J.G, J.G.,
- C.J.T., J.A.H., G.M., R.J.W, K.C.O. Clinical data curation: K.Z., K.D.D., K.B.C., J.H.K.,
- V.E.D., E.Q.G., B.C., D.J.G, J.G., C.J.T., J.A.H., G.M, K.C.O. Writing (original draft): A.B.,
- J.L.D. Writing (review and editing): A.B., K.C.O., P.J.U., J.A.H, S.W.J., M.S.A., J.L.D.
- Supervision: P.J.U., J.A.H, S.W.J., M.S.A., J.L.D.
- 

# **Competing Interest Declaration**

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

#### **Funding**

- This work was supported by the Pediatric Scientist Development Program and the Eunice
- Kennedy Shriver National Institute of Child Health and Human Development grant K12-
- HD000850 (A.B.), and by the Chan Zuckerberg Biohub SF (J.L.D. and M.S.A.), and by National
- Institutes of Health grants R01AR073938 and R01AR075813 (S.W.J) and by and the National
- Cancer Institute (U01CA247548 to J.A.H.) and by the National Institute of Allergy and
- Infectious Diseases of the NIH under award numbers R01-AI114780(K.C.O), R21-
- AI142198(K.C.O), R21 AI164590 (K.C.O) and through an awards provided through award
- number U54-NS115054 (K.C.O) and NIH U54 NS115054 (G.M and R.J.N; G.M is also an
- MGNet Scholar Awardee) of the Rare Diseases Clinical Research Network Consortium
- (RDCRN) of the NIH and MGNet. All RDCRN consortia are supported by the network's Data
- Management and Coordinating Center (DMCC) (U2CTR002818). This study was supported by
- NIH-NIA grants R01AG032289 (J.H.K) and R01AG072475(K.B.C), UCSF ADRC
- P30AG062422 (G.D.R), This work was also supported by a grant from the Larry L. Hillblom
- Foundation (2018-A-006-NET; J.H.K). This work was also supported by the Henry Gustav
- Floren Trust, the Stanford Department of Medicine Team Science Program, and funding from
- 834 the Stanford Medicine Office of the Dean (P.J.U.).
- 

### **Potential Conflicts**

- J.D.R. reports being a founder and paid consultant for Delve Bio, Inc., and a paid consultant for
- 838 the Public Health Company and Allen & Co. M.A.S. receives unrelated research funding from
- the NIH, the CDC, Cepheid and Merck and unrelated Honoria from UpToDate, Inc. M.R.W.
- reports being a founder and paid consultant for Delve Bio, Inc. and receives unrelated research
- grant funding from Roche/Genentech and Novartis, and received speaking honoraria from
- Genentech, Takeda, WebMD, and Novartis. C.J.T. reports being on the Scientific Advisory
- Boards for Caribou Biosciences, T-CURX, Myeloid Therapeutics, ArsenalBio, Cargo
- Therapeutics, Celgene/BMS Cell Therapy; is a member a DSMB member of Kyverna; is on Ad hoc advisory boards/consulting (last 12 months) for Nektar Therapeutics, Legend Biotech,
- Prescient Therapeutics, Century Therapeutics, IGM Biosciences, Abbvie; has Stock options in
- Eureka Therapeutics, Caribou Biosciences, Myeloid Therapeutics, ArsenalBio, Cargo
- Therapeutics; and reports the right to receive payment from Fred Hutch as an inventor on patents
- related to CAR T-cell therapy. J.A.H. reports research funding from Merck and Takeda and
- consulting fees from Takeda, Gilead, SentiBio, and Century Therapeutics. J.G. reports research
- funding from Sobi, Juno Therapeutics (a BMS company), Celgene (a BMS company),
- Angiocrine Bioscience; is an Ad hoc consultant for Sobi, Legend Biotech, Janssen, Kite Pharma,
- MorphoSys. D.J.G. has received research funding, has served as an advisor and has received
- royalties from Juno Therapeutics, a Bristol-Myers Squibb company; has served as an advisor and
- received research funding from Seattle Genetics; has served as an advisor for GlaxoSmithKline,
- Celgene, Janssen Biotech, Ensoma and Legend Biotech; and has received research funding from
- SpringWorks Therapeutics, Sanofi, and Cellectar Biosciences. K.C.O. received unrelated
- research funding from, and is an equity shareholder of Cabaletta Bio, and receives unrelated
- research funding from Seismic, argenx, and Viela Bio/Horizon (now Amgen). R.J.N. reports
- unrelated research support from the National Institutes of Health, Genentech, Inc., Alexion
- Pharmaceuticals, Inc., argenx, Annexon Biosciences, Inc., Ra Pharmaceuticals, Inc. (now UCB
- S.A.), the Myasthenia Gravis Foundation of America, Inc., Momenta Pharmaceuticals, Inc. (now
- Janssen), Immunovant, Inc., Grifols, S.A., and Viela Bio, Inc. (now Horizon Therapeutics plc).

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

- 864 R.J.N. has also served as a consultant/advisor unrelated to research in this manuscript for
- 865 Alexion Pharmaceuticals, Inc., argenx, Cabaletta Bio, Inc., Cour Pharmaceuticals, CSL Behring,
- 866 Grifols, S.A., Ra Pharmaceuticals, Inc. (now UCB S.A.), Immunovant, Inc., Momenta
- 867 Pharmaceuticals, Inc. (now Janssen), and Viela Bio, Inc. (now Horizon Therapeutics plc). J.L.D.,
- 868 C.M.B. and M.R.W. receive licensing fees from CDI Labs.
- 869
- 870 **Correspondence and requests for materials should be addressed to Mark S. Anderson**  871 **[\(mark.anderson@ucsf.edu\)](mailto:mark.anderson@ucsf.edu) and Joseph L. DeRisi [\(joe@derisilab.ucsf.edu\)](mailto:joe@derisilab.ucsf.edu).**
- 872

### 873 **Extended Data Figures and Tables**

874

### 875 **Extended Data Figure 1. Administration of IVIG minimally alters the autoreactome**

![](_page_26_Figure_13.jpeg)

876<br>877

877 **(a)** Correlation matrices showing Pearson correlation coefficients of complete PhIP-Seq signal 878 before and after IVIG administration. **(b)** Kernel density estimate plot showing distribution of

879 Pearson R correlation coefficients from before and after IVIG administration relative to

- 880 longitudinal samples from individuals over time, and between different individuals. **(c)** Lineplots
- 881 showing the autoreactivity (sum of top 10 PhIP-Seq Z-scores relative to the 79 healthy controls)
- 882 for each patient before and after IVIG administration. Paired-samples Wilcoxon test p-value

883 0.625.

884

#### 885 **Extended Data Figure 2. Changes in disease-causing autoantibody levels following**  886 **rituximab**

![](_page_26_Figure_23.jpeg)

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

**Left**: Anti-AChR autoantibody levels measured by radioimmunoassay (RIA; Mayo Clinic

Laboratory, unit=nmol/L) in 2 patients at 1 month, 3 months, and 6 months post-rituximab. RIA

- positive cutoff 0.02 nmol/L. **Right**: Anti-MuSK autoantibody titers measured by RIA (Athenia
- Diagnostics, unit=fold dilution) in a different 4 patients at 1 month, 3 months, and 6 months
- post-rituximab. Positive cutoff for is a fold dilution of greater than 1:20.
- 

#### **Extended Data Figure 3: CD19 cell counts following anti-CD19 CAR-T treatment**

![](_page_27_Figure_10.jpeg)

897<br>898

Lineplots showing the levels of  $CD19<sup>+</sup>$  B cells in peripheral blood measured by flow cytometry

at various timepoints relative to anti-CD19 CAR-T treatment, in each patient.

- **Extended Data Figure 4: Changes in multiplex bead-based protein array detected antibody**
- **levels following CD19 therapy**

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

![](_page_28_Figure_2.jpeg)

903<br>904 (a) Multiplex bead-based protein array detected normalized MFI values (see "Methods") for each of the 16 autoantigens with meaningful signal (see "Methods") in each of the patients before and approximately 6 months after treatment with anti-CD19 CAR-T cells. P-values shown are from a paired-samples Wilcoxon test. **(b)** Multiplex bead-based protein array detected normalized MFI values (see "Methods") for each of the 17 viral antigens with meaningful signal (see "Methods") in each of the patients before and after treatment with anti-CD19 CAR-T cells. P-values shown are from a paired-samples Wilcoxon test.

- 911
- 912

# 913 **Extended Data Figure 5: Changes in bone marrow plasma cell percentage following anti-**

914 **BCMA CAR-T cell therapy**

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

![](_page_29_Figure_2.jpeg)

![](_page_29_Figure_4.jpeg)

917 various timepoints relative to anti-BCMA CAR-T treatment, in each patient.

918

919 **Extended Data Figure 6: Changes in PhIP-Seq detected autoreactivities following anti-**

![](_page_29_Figure_8.jpeg)

![](_page_29_Figure_9.jpeg)

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

- 922 **(a)** Lineplots showing the autoreactivity (sum of top 10 PhIP-Seq Z-scores relative to the 79
- 923 healthy controls) for each patient before and after treatment. One-sided paired samples Wilcoxon
- 924 test p-value=0.049. **(b)** Swarmplots showing the relative distributions of autoreactivity (sum of
- 925 top 10 PhIP-Seq Z-scores relative to the 79 healthy controls) before and after treatment with anti-
- 926 BCMA CAR-T. Mann-Whitney U p-value=0.006. **(c)** Boxplots showing the relative distributions
- 927 of autoreactivity (sum of top 10 PhIP-Seq Z-scores relative to the 79 healthy controls) before and 928 after treatment with rituximab, anti-CD19 CAR-T, and anti-BCMA CAR-T. rituximab treatment
- 929 cohort Mann-Whitney U p-value=0.42 with a median percent decrease of 52.3%; anti-CD19
- 930 CAR-T treatment cohort Mann-Whitney U p-value=0.206 with a median percent decrease of
- 931 11.9%; anti-BCMA CAR-T treatment cohort Mann-Whitney U p-value=0.006 with a median
- 932 percent decrease of 97.2%.
- 933

### 934 **Extended Data Figure 7: Changes in multiplex bead-based protein array detected antibody**  935 **levels following BCMA therapy**

![](_page_30_Figure_14.jpeg)

936<br>937

937 **(a)** Multiplex bead-based protein array detected normalized MFI values (see "Methods") for each 938 of the 16 autoantigens with meaningful signal (see "Methods") in each of the patients before and

939 after treatment with anti-BCMA CAR-T cells. P-values shown are from a paired-samples

940 Wilcoxon test. **(b)** Multiplex bead-based protein array detected normalized MFI values (see

941 "Methods") for each of the 17 viral antigens with meaningful signal (see "Methods") in each of

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

- 942 the patients before and after treatment with anti-BCMA CAR-T cells. P-values shown are from a
- 943 paired-samples Wilcoxon test.
- 944

### **Extended Data Figure 8: Flow cytometry gating strategy for identification of CD19<sup>+</sup> B cells**

![](_page_31_Figure_6.jpeg)

Representative flow cytometry gating for the identification and enumeration of  $CD19<sup>+</sup>$  B-cells.

946<br>947

948

#### 949 **Extended Data Table 1: PhIP-Seq Cohort Demographics**

![](_page_31_Picture_499.jpeg)

950 \* Age ranges at time of first sample collection: 26-30 years, n=1; 31-35 years, n=1; 35-40 years,

951 n=1; 51-55 years, n=1.

952 \*\*Age ranges at time of first sample collection: <20 year old, n=1; 21-25 years, n=1; 35-40

953 years, n=1; 61-65 years, n=2, 66-70 years, n=2.

954

#### 955 **Extended Data Table 2: Healthy Longitudinal Patient Clinical Details**

![](_page_31_Picture_500.jpeg)

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

![](_page_32_Picture_296.jpeg)

956<br>957

### 957 **Extended Data Table 3: IVIG Sample Details**

![](_page_32_Picture_297.jpeg)

958<br>959

### 959 **Extended Data Table 4: Rituximab Sample Details**

![](_page_32_Picture_298.jpeg)

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

![](_page_33_Picture_319.jpeg)

960

961

### 962 **Extended Data Table 5. CAR-T Sample Details**

![](_page_33_Picture_320.jpeg)

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

![](_page_34_Picture_352.jpeg)

963

964 **Table Legend:** MM=multiple myeloma; Sample timing refers to number of weeks between

965 CAR-T infusion and the post-infusion sample being drawn; Prior therapy lists additional

966 immunomodulatory therapies given in the year prior to initial sample collection, and the number

967 of months between administration of the therapy and collection of the initial sample, excluding

968 the pre-CAR-T conditioning chemotherapy which consists of cyclophosphamide and fludarabine

969 for every patient; Concurrent treatment lists the number of days prior to the second sample being

970 collected when treatment was administered, only IVIG is listed because no other B cell or

- 971 antibody modulating therapies were given.
- 972

### 973 **Extended Data Table 6: Multiplex Bead-based Protein Array Antigen Panel**

![](_page_34_Picture_353.jpeg)

![](_page_35_Picture_257.jpeg)

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

![](_page_36_Picture_288.jpeg)

974<br>975

**Extended Data Table 7: Additional BCMA Patient Demographics** 

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

![](_page_37_Picture_215.jpeg)

976

#### 977 **Extended Data Table 8: Additional BCMA Sample Details**

![](_page_37_Picture_216.jpeg)

978<br>979

Table Legend: MM=multiple myeloma; Sample timing refers to number of weeks between

980 CAR-T infusion and the post-infusion sample being drawn; Prior therapy lists additional

981 immunomodulatory therapies given in the year prior to initial sample collection, and the number

982 of months between administration of the therapy and collection of the initial sample, excluding

983 the pre-CAR-T conditioning chemotherapy which consists of cyclophosphamide and fludarabine

984 for every patient.

985